Pneumagen Targeting The Human Glycome To Block Viral Entry
COVID-19 Among Potential Uses
Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.
